Cotinga Looks to Expand COTI-2 Trial to Include Other Therapy Combos

Cotinga Looks to Expand COTI-2 Trial to Include Other Therapy Combos
Cotinga Pharmaceuticals is seeking approval from the U.S. Food and Drug Administration (FDA) to expand its ongoing Phase 1 trial of COTI-2 to include combination therapies and a broader spectrum of cancer types. The clinical trial (NCT02433626) is currently assessing the safety and tolerability of COTI-2 in patients with head and neck squamous cell carcinoma (HNSCC)

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *